Outcomes of unplanned tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: retrospective analysis of real-world experience in a single institution.
Masaki IinoTakeo YamamotoYuma SakamotoPublished in: Hematology (Amsterdam, Netherlands) (2019)
TKI was safely discontinued in clinical practice and yielded TFR rates similar to those observed in previous clinical trials, regardless of reason. Achievement of TFR significantly impacts patients' quality of life and should be considered in clinical practice.
Keyphrases
- clinical practice
- chronic myeloid leukemia
- clinical trial
- end stage renal disease
- newly diagnosed
- ejection fraction
- chronic kidney disease
- prognostic factors
- type diabetes
- tyrosine kinase
- randomized controlled trial
- patient reported outcomes
- advanced non small cell lung cancer
- metabolic syndrome
- adipose tissue
- weight loss
- open label
- phase iii